Skip to main content

Table 1 Patient demographic and clinical characteristics

From: Clinical utility of cerebrospinal fluid-derived circular RNAs in lung adenocarcinoma patients with brain metastases

Character N (%)
Total N = 21
Age at baseline, years
 Median 55
 Range 39–74
Sex
 Male 9 (43%)
Smoking status
 Current smoker 1 (5%)
 Former smoker 5 (24%)
 Never smoker 15 (71%)
Activating mutation
 EGFR mut 17(81%)
 ALK rearrangement 3 (14%)
 KRAS mut 1 (5%)
LMC
 Yes* 5 (24%)
Baseline PS
 0 1 (5%)
 1 19 (90%)
 2 1 (5%)
Treatment received
 TKI** 9 (43%)
 TKI + SRS of BM 3 (14%)
 TKI + resection of BM 1 (5%)
 TKI + bev 1 (5%)
Chemotherapy 3 (14%)
 Pem + CBP + Bev 1 (5%)
 Pem + Bev 1 (5%)
 Paclitaxel + CBP + Bev 1 (5%)
WBI + BSC 2 (10%)
BSC 2 (10%)
  1. EGFR epidermal growth factor receptor, ALK anaplastic lymphoma kinase, KRAS Kirsten rat sarcoma viral oncogene homologue, mut mutant, BM brain metastasis, LMC leptomeningeal carcinomatosis, PS performance status, TKI tyrosine kinase inhibitor, SRS stereotactic radiosurgery, Pem pemetrexed, CBP carboplatin, Bev bevacizumab, WBI whole brain irradiation, BSC best support care
  2. *Patient was considered to have LMC should had at least one positive result of cerebrospinal fluid (CSF) cytology and brain magnetic resonance imaging (MRI). Three patients were diagnosed with LMC by CSF cytology, brain MRI, accompanied by neurological symptoms, which included headache, confusion, cognitive impairment and psychiatric disorders. The other two patients were diagnosed with LMC by brain MRI without symptom or CSF cytology
  3. **Details of TKI regimens are shown in Additional file 5: Table S5